Cyclacel Pharms

CYCC NASDAQ
0.7630
+0.1389
+22.26%
After Hours: 0.7600 -0.003 -0.39% 19:51 05/24 EDT
Open
0.8223
Prev Close
0.6241
High
1.020
Low
0.7050
Volume
27.97M
Avg Vol (3M)
1.17M
52 Week High
1.870
52 Week Low
0.5100
% Turnover
162.62%
Market Cap
13.12M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Cyclacel Pharms CYCC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
MORE >

Recently

Name
Price
%Change